Search hospitals > Michigan > Detroit
Barbara Ann Karmanos Cancer Institute
Claim this profileDetroit, Michigan 48201
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Lymphoma
Conducts research for Breast Cancer
Conducts research for Lung Cancer
1496 reported clinical trials
99 medical researchers
Summary
Barbara Ann Karmanos Cancer Institute is a medical facility located in Detroit, Michigan. This center is recognized for care of Cancer, Tumors, Lymphoma, Breast Cancer, Lung Cancer and other specialties. Barbara Ann Karmanos Cancer Institute is involved with conducting 1,496 clinical trials across 810 conditions. There are 99 research doctors associated with this hospital, such as Ammar Sukari, Hirva Mamdani, MD, Anthony F. Shields, and Dipenkumar Modi, M.D..Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Tumors
Global LeaderStage IV
Stage III
HER2 positive
Top PIs
Ammar SukariWayne State University/Karmanos Cancer Institute1 year of reported clinical research
Expert in Cancer
Expert in Squamous Cell Carcinoma
26 reported clinical trials
43 drugs studied
Hirva Mamdani, MDKarmanos Cancer Institute4 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Studies Lung Cancer
20 reported clinical trials
29 drugs studied
Anthony F. ShieldsBarbara Ann Karmanos Cancer Institute4 years of reported clinical research
Studies Tumors
Studies Solid Tumors
20 reported clinical trials
62 drugs studied
Dipenkumar Modi, M.D.Karmanos Cancer Institute1 year of reported clinical research
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
19 reported clinical trials
45 drugs studied
Clinical Trials running at Barbara Ann Karmanos Cancer Institute
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Breast Cancer
Esophageal Carcinoma
Prostate Cancer
Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Esophageal Cancer
Gastric Cancer
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This study is evaluating whether the addition of radiation therapy to chemotherapy may help treat patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Proton Therapy vs Photon Radiation
for Esophageal Cancer
This study is evaluating whether a type of radiation therapy may be more effective than another type of radiation therapy in treating esophageal cancer.
Recruiting2 awards Phase 31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Barbara Ann Karmanos Cancer Institute?
Barbara Ann Karmanos Cancer Institute is a medical facility located in Detroit, Michigan. This center is recognized for care of Cancer, Tumors, Lymphoma, Breast Cancer, Lung Cancer and other specialties. Barbara Ann Karmanos Cancer Institute is involved with conducting 1,496 clinical trials across 810 conditions. There are 99 research doctors associated with this hospital, such as Ammar Sukari, Hirva Mamdani, MD, Anthony F. Shields, and Dipenkumar Modi, M.D..
Where is Barbara Ann Karmanos Cancer Institute located?
The Barbara Ann Karmanos Cancer Institute, situated in midtown Detroit, MI at 4100 John R St, is the sole National Cancer Institute (NCI)-designated comprehensive cancer center in southeast Michigan. It stands among only 54 centers of its kind across the United States.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance and Insurance Inquiries at Barbara Ann Karmanos Cancer Institute:**
- For financial assistance, contact McLaren Patient Financial Services at (844) 321-1557 or submit the Financial Assistance Application to: McLaren Corporate Services, Attn: Revenue Cycle Operations, 50820 Schoenherr Rd., Shelby Township, MI 48315.
- For insurance-related questions, call the hospital's general information line at 1-800-KARMANOS (1-800-527-6266).
What insurance does Barbara Ann Karmanos Cancer Institute accept?
The Barbara Ann Karmanos Cancer Institute accepts most health insurance plans, including Aetna, Blue Cross Blue Shield of MI, Cigna, Humana, Molina, and United Health Care among others. It is crucial to verify with your insurance provider about coverage for procedures at the Karmanos Cancer Institute before scheduling your first appointment. Patients are encouraged to review their insurance coverage annually to avoid unexpected bills.
What awards or recognition has Barbara Ann Karmanos Cancer Institute received?
The Barbara Ann Karmanos Cancer Institute, located in Detroit, Michigan, was awarded a $352,437 grant by the U CAN-CER VIVE Foundation in 2022 to support its research efforts. It has been recognized as a National Cancer Institute (NCI)-designated comprehensive cancer center since 1978, a testament to its scientific excellence and integrated research approaches in the fight against cancer.